5Eastell R,Brainbridge PR.Bone turnover markers:their place in the investigation of osteoprosis.In:Osteoprosis:Pathophysiology and clinical management(eds by Orwoll ES,Bliziotes M).Humans Press Totowa.NJ,2003.185-197.
6looker A,Bauer DC,Cheanut C Ⅲ,et al.Clinical use of biochemical markers of bone remodeling:current status,future direction.Osteoporos Int,2000,11:467-480.
7NIH Consensus Development Panel on Osteoporosis Prevention.Diagnosis and Therapy.JAMA,2001,285:785-795.
8Heaney RP.Is the paradigm shifting.Bone,2003,33:457-465.
9Garnero P,Sornay-Rendu E,Claustrar B,et al.Biochemical markets of bone turnover.endogenous hormones and the risk of fracture in postmenpausal women:the OFELY study.J Bone Minter Res,2000,15:1526-1536.
10Ross PD,Kress BC,Parson RE,et al.Serum bone alkaline phosphatase and calcaneus bone density predict fractures:a prospective study.Ostteoporos Int,2000,11:76-82.
7McClung MR, Siris E, Cummings S, et al. Preven- tion of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene [J].Menopause, 2006, 13(3): 377-386.
